{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:29:49Z","timestamp":1770283789223,"version":"3.49.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2010,6,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> Women (who had performance status [PS] of 0 to 1) with operable, histologically confirmed, stage I to III adenocarcinoma of the breast were eligible. Patients had undergone primary surgery with no residual tumor. Treatments were as follows: arm 1 was doxorubicin 60 mg\/m<jats:sup>2<\/jats:sup> plus cyclophosphamide 600 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks for four cycles followed by paclitaxel 175 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks for four cycles (ie, AC-P); and arm 2 was doxorubicin 50 mg\/m<jats:sup>2<\/jats:sup> plus paclitaxel 200 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks for four cycles followed by paclitaxel 80 mg\/m<jats:sup>2<\/jats:sup> weekly for 12 weeks. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Overall, 1,830 patients were enrolled and 1,801 were treated: arm 1 (n = 906; AC\u2192P) and arm 2 (n = 895; AP-WP). Overall, patients had a PS of 0 (88%), had estrogen receptor and progesterone receptor\u2013positive disease (52%), had one to three positive nodes (46%), and were postmenopausal (57%); the median age was 52 years. Currently, 1,640 patients (90%) are alive. The 6-year DFS was 79% to 80% in both groups. Disease relapse was the cause of death for 83 patients in arm 1 and in 66 patients of arm 2. Overall 6-year survival rates were 82% and 87% in arms 1 and 2, respectively. Reasons for patients being taken off study treatment included toxicity (13% in arm 1 v 20% in arm 2), progressive disease or recurrence (7% v 5%), and consent withdrawn (9% v 8%), respectively. The most frequent toxicities were hematologic, including neutropenia and leukopenia followed by neuropathy, myalgia, nausea, fatigue, headache, arthralgia, and vomiting. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The results indicate that the AP-WP regimen is an equally effective and tolerable option for the adjuvant treatment of patients with high-risk breast cancer. The substitution of paclitaxel for cyclophosphamide results in comparable effectiveness of the regimen. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2009.24.1000","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T03:49:43Z","timestamp":1274154583000},"page":"2958-2965","source":"Crossref","is-referenced-by-count":18,"title":["Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer"],"prefix":"10.1200","volume":"28","author":[{"given":"David","family":"Loesch","sequence":"first","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil N.","family":"Senzer","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jones","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetislava J.","family":"Vukelja","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sandbach","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frankie","family":"Holmes","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Pippen","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Lindquist","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi","family":"McIntyre","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L.","family":"Blum","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel R.","family":"Modiano","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi A.","family":"Boehm","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhan","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Robert","sequence":"additional","affiliation":[{"name":"From the US Oncology Research, The Woodlands; Mary Crowley Cancer Center; Texas Oncology PA at Baylor, Charles A. Sammons Cancer Center; and Texas Oncology PA, Dallas; Texas Oncology PA, Tyler; Texas Oncology PA, Austin; and Texas Oncology PA, Houston, TX; Rocky Mountain Cancer Centers, Denver, CO; Northern Arizona Hematology Oncology Associates, Sedona; Arizona Oncology Associates PC; and Arizona Clinical Research Center, Tucson, AZ; Fairfax Northern Virginia Hematology\/Oncology, Fairfax, VA; and Sarah..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr070105"},{"key":"B4","first-page":"1","volume":"26","author":"Norton L","year":"1999","journal-title":"Semin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9651-3"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.072"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.037"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000025405.63953.f9"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.013"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10914"},{"key":"B11","first-page":"3360","volume":"8","author":"Giordano SH","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/030089160108700104"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.005"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2688"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3353"},{"key":"B16","first-page":"S1","volume":"24","author":"Gianni L","year":"1997","journal-title":"Semin Oncol"},{"key":"B17","first-page":"13","volume":"12","author":"Gianni L","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"B18","first-page":"101a","volume":"17","author":"Henderson IC","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B19","unstructured":"ID Fleming,  JS Cooper,  DE Henson , etal:  AJCC Cancer Staging Manual (ed 5), American Joint Committee on Cancer 1997 Philadelphia, PA Lippincott-Raven"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2624"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3391"},{"key":"B23","first-page":"73a","volume":"18","author":"Pouillart P","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.122"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707056"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040331"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"B28","volume":"18","author":"Berry D","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4501"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5391"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041588"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021967"},{"key":"B33","first-page":"266","volume":"1796","author":"Jaspers JE","year":"2009","journal-title":"Biochimica et Biophysica Acta"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.063"},{"key":"B35","first-page":"619","volume":"12","author":"Ocean AJ","year":"2004","journal-title":"Support Care Cancer"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2009.24.1000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:17:31Z","timestamp":1653524251000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2009.24.1000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,20]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2010,6,20]]}},"alternative-id":["10.1200\/JCO.2009.24.1000"],"URL":"https:\/\/doi.org\/10.1200\/jco.2009.24.1000","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,20]]}}}